<p>Balchem（BCPC）已召开其第四季度财报电话会议。以下是会议的主要亮点。</p>
<h3>总统日促销 - 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Balchem 最新的财报电话会议语气相当乐观，管理层强调了创纪录的财务业绩和各业务部门的稳定执行。高管们承认由于更高的投入成本和监管不确定性带来的压力，但反复强调定价能力、供应链灵活性和稳健的资产负债表是公司能够持续增加收益的原因。</p>
<h2>创纪录的全年财务数据凸显增长故事</h2>
<p>Balchem 公布了创纪录的 2025 年业绩，销售额增长 8.8% 至 10.37 亿美元，运营收益增长 14.4% 至 2.09 亿美元。调整后的 EBITDA 达到历史最高水平 2.75 亿美元，增长 9.8%，而自由现金流在投资 4300 万美元后仍达到创纪录的 1.74 亿美元。</p>
<h2>第四季度实现双位数收益和每股收益增长</h2>
<p>2025 年第四季度收入同比增长 9.8% 至 2.64 亿美元，GAAP 运营收益增长 10.2% 至 5200 万美元。调整后的 EBITDA 增长 8.1% 至 6800 万美元，支持 25.8% 的利润率，而净收入增长 16.8% 至 3900 万美元，稀释后的 GAAP 每股收益增长 17.5% 至 1.21 美元。</p>
<h2>连续二十六个季度的 EBITDA 增长</h2>
<p>管理层强调第四季度是公司连续第 26 个季度实现同比调整后 EBITDA 增长，这在市场周期中是一个异常长的记录。这种一致性表明 Balchem 的产品组合和定价纪律有效抵消了成本波动和终端市场的疲软。</p>
<h2>人类营养与健康强劲势头</h2>
<p>人类营养与健康继续推动增长，第四季度该部门销售额增长 12.7% 至 1.66 亿美元，运营收益增长 8.9% 至 3700 万美元。营养素和食品成分与解决方案的广泛增长得益于推动对强化和功能性食品需求的 “更健康” 消费趋势。</p>
<h2>动物营养与健康显现复苏迹象</h2>
<p>在动物营养与健康方面，第四季度销售额增长 4.9% 至 6100 万美元，运营收益增长 8.6% 至 600 万美元。反刍动物业务正在获得市场份额，管理层指出在反倾销措施后，欧洲单胃动物市场出现早期复苏迹象，尽管他们警告说仍处于初期阶段。</p>
<h2>特殊产品受益于气体和植物营养</h2>
<p>特殊产品在第四季度实现销售额 3500 万美元，同比增长 6%，运营收益增长 5.5% 至 1100 万美元。增长主要得益于性能气体和植物营养产品，以及持续的地理扩张，扩大了该部门的可服务市场。</p>
<h2>强劲的现金生成、降低杠杆、股东回报</h2>
<p>Balchem 在第四季度结束时拥有 7500 万美元现金，并将净债务削减至 8900 万美元，意味着净杠杆约为 0.3 倍。该季度的经营现金流达到 6700 万美元，使得以约 158 美元的平均价格回购约 68.5 万股，并将股息提高 10% 至 0.96 美元。</p>
<h2>科学、临床管道和品牌合作作为增长引擎</h2>
<p>管理层强调 2025 年有超过 20 项活跃的临床研究和 18 篇出版物作为支撑未来需求和高端定位的关键资产。包括 VitaCholine 和 K2VITAL 的体育合作在内的高调市场营销合作正在带来令人鼓舞的采用，同时在纽约的新微胶囊设施建设已开始。</p>
<h2>可持续性在减排方面取得进展，水资源方面仍需努力</h2>
<p>在可持续性方面，Balchem 已经超过了 2030 年温室气体减排目标，与 2020 年水平相比减少了约 31%。水资源提取量较同一基线下降约 16%，虽然取得了进展，但仍未达到 25% 的减排目标，留有进一步改善的空间。</p>
<h2>关税、供应链韧性和外汇顺风</h2>
<p>公司估计，潜在的美国关税暴露约为 2000 万美元，通过替代采购和定价措施削减至约 1000 万美元。管理层还指出，2025 年的业绩在外汇方面略有受益，美元/欧元的变动为全年增长贡献了约 0.7%，对第四季度增长贡献略超过 1%。</p>
<h2>利润率受到投入成本和更高运营费用的压力</h2>
<p>尽管第四季度的毛利润有所增加，但由于制造投入成本上升，毛利率同比下降约 40 个基点至 35.6%。运营费用增长约 7% 至 4200 万美元，主要由于薪酬，部分抑制了利润率的扩张，尽管基础收益依然强劲。</p>
<h2>监管和市场不确定性仍在关注之中</h2>
<p>管理层指出，最近一项影响关税规则的高等法院裁决是近期规划不确定性的来源，可能会导致替代关税或退款。他们还提到约 1000 万美元的剩余关税成本暴露、欧洲单胃动物市场的早期复苏以及温和但上升的外汇敏感性是需要关注的领域。</p>
<h2>前瞻性指导和资本优先事项</h2>
<p>展望 2026 年，Balchem 在定性上指导继续实现收入和利润的增长，同时推进临床、产能和商业计划。公司要求投资者将有效税率建模在 23% 左右，并重申有机投资和收购、债务减少、持续的股息增长以及在低杠杆位置下的机会性回购作为资本优先事项。</p>
<p>拜切公司的财报电话会议描绘了一幅公司稳健执行与严谨资产负债管理相结合的画面。创纪录的业绩、持续的 EBITDA 增长和积极的资本回报被可控的原材料成本和监管压力所抵消，使投资者对公司的发展前景普遍持乐观态度。</p>

拜切公司

<p>Balchem 第四季度的财报电话会议强调了创纪录的增长，2025 年的销售额增长 8.8%，达到 10.37 亿美元，运营收益增长 14.4%，达到 2.09 亿美元。该公司报告了连续第 26 个季度的调整后 EBITDA 增长，这得益于人类营养与健康领域的强劲表现。尽管面临原材料成本和监管不确定性的挑战，Balchem 稳健的资产负债表和定价能力支持了持续增长。公司还宣布了 10% 的股息增加和股票回购，同时在可持续发展目标上取得了进展</p>

<p>Balchem ((BCPC)) has held its Q4 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Balchem（BCPC）已召开其第四季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>President's Day Sale - 70% Off</h3>
<div class="lb-trans"><h3>总统日促销 - 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Balchem’s latest earnings call struck a decidedly upbeat tone, with management spotlighting record financial results and steady execution across all business segments. Executives acknowledged pockets of pressure from higher input costs and regulatory uncertainty, but repeatedly emphasized pricing power, supply-chain agility, and a solid balance sheet as reasons the company can keep compounding earnings.</p>
<div class="lb-trans"><p>Balchem 最新的财报电话会议语气相当乐观，管理层强调了创纪录的财务业绩和各业务部门的稳定执行。高管们承认由于更高的投入成本和监管不确定性带来的压力，但反复强调定价能力、供应链灵活性和稳健的资产负债表是公司能够持续增加收益的原因。</p>
</div><h2>Record Full-Year Financials Underscore Growth Story</h2>
<div class="lb-trans"><h2>创纪录的全年财务数据凸显增长故事</h2>
</div><p>Balchem posted record 2025 results, with sales rising 8.8% to $1.037 billion and earnings from operations climbing 14.4% to $209 million. Adjusted EBITDA hit an all-time high of $275 million, up 9.8%, while free cash flow reached a record $174 million even after $43 million of capital investment.</p>
<div class="lb-trans"><p>Balchem 公布了创纪录的 2025 年业绩，销售额增长 8.8% 至 10.37 亿美元，运营收益增长 14.4% 至 2.09 亿美元。调整后的 EBITDA 达到历史最高水平 2.75 亿美元，增长 9.8%，而自由现金流在投资 4300 万美元后仍达到创纪录的 1.74 亿美元。</p>
</div><h2>Q4 Delivers Double-Digit Earnings and EPS Gains</h2>
<div class="lb-trans"><h2>第四季度实现双位数收益和每股收益增长</h2>
</div><p>Fourth-quarter 2025 revenue grew 9.8% year over year to $264 million, with GAAP earnings from operations up 10.2% to $52 million. Adjusted EBITDA rose 8.1% to $68 million, supporting a 25.8% margin, while net income increased 16.8% to $39 million and diluted GAAP EPS advanced 17.5% to $1.21.</p>
<div class="lb-trans"><p>2025 年第四季度收入同比增长 9.8% 至 2.64 亿美元，GAAP 运营收益增长 10.2% 至 5200 万美元。调整后的 EBITDA 增长 8.1% 至 6800 万美元，支持 25.8% 的利润率，而净收入增长 16.8% 至 3900 万美元，稀释后的 GAAP 每股收益增长 17.5% 至 1.21 美元。</p>
</div><h2>Twenty-Six Straight Quarters of EBITDA Growth</h2>
<div class="lb-trans"><h2>连续二十六个季度的 EBITDA 增长</h2>
</div><p>Management highlighted Q4 as the company’s 26th consecutive quarter of year-over-year adjusted EBITDA growth, an unusually long streak across market cycles. This consistency suggests Balchem’s portfolio and pricing discipline are effectively offsetting cost volatility and pockets of end-market softness.</p>
<div class="lb-trans"><p>管理层强调第四季度是公司连续第 26 个季度实现同比调整后 EBITDA 增长，这在市场周期中是一个异常长的记录。这种一致性表明 Balchem 的产品组合和定价纪律有效抵消了成本波动和终端市场的疲软。</p>
</div><h2>Human Nutrition &amp; Health Leads with Strong Momentum</h2>
<div class="lb-trans"><h2>人类营养与健康强劲势头</h2>
</div><p>Human Nutrition &amp; Health continued to power growth, with Q4 segment sales rising 12.7% to $166 million and earnings from operations up 8.9% to $37 million. Gains were broad-based across Nutrients and Food Ingredients &amp; Solutions, supported by “better-for-you” consumer trends that are driving demand for fortified and functional foods.</p>
<div class="lb-trans"><p>人类营养与健康继续推动增长，第四季度该部门销售额增长 12.7% 至 1.66 亿美元，运营收益增长 8.9% 至 3700 万美元。营养素和食品成分与解决方案的广泛增长得益于推动对强化和功能性食品需求的 “更健康” 消费趋势。</p>
</div><h2>Animal Nutrition &amp; Health Shows Signs of Recovery</h2>
<div class="lb-trans"><h2>动物营养与健康显现复苏迹象</h2>
</div><p>In Animal Nutrition &amp; Health, Q4 sales increased 4.9% to $61 million, while earnings from operations improved 8.6% to $6 million. The ruminant business is gaining penetration, and management pointed to early signs of recovery in European monogastric markets following antidumping actions, though they cautioned it is still early days.</p>
<div class="lb-trans"><p>在动物营养与健康方面，第四季度销售额增长 4.9% 至 6100 万美元，运营收益增长 8.6% 至 600 万美元。反刍动物业务正在获得市场份额，管理层指出在反倾销措施后，欧洲单胃动物市场出现早期复苏迹象，尽管他们警告说仍处于初期阶段。</p>
</div><h2>Specialty Products Benefit from Gases and Plant Nutrition</h2>
<div class="lb-trans"><h2>特殊产品受益于气体和植物营养</h2>
</div><p>Specialty Products delivered Q4 sales of $35 million, up 6% year over year, with earnings from operations advancing 5.5% to $11 million. Growth was driven by Performance Gases and Plant Nutrition offerings, alongside ongoing geographic expansion that is broadening the segment’s addressable market.</p>
<div class="lb-trans"><p>特殊产品在第四季度实现销售额 3500 万美元，同比增长 6%，运营收益增长 5.5% 至 1100 万美元。增长主要得益于性能气体和植物营养产品，以及持续的地理扩张，扩大了该部门的可服务市场。</p>
</div><h2>Robust Cash Generation, Lower Leverage, Shareholder Returns</h2>
<div class="lb-trans"><h2>强劲的现金生成、降低杠杆、股东回报</h2>
</div><p>Balchem closed Q4 with $75 million of cash and trimmed net debt to $89 million, implying net leverage of about 0.3 times. Operating cash flow reached $67 million in the quarter, enabling repurchases of roughly 685,000 shares at an average price of about $158 and a 10% dividend increase to $0.96.</p>
<div class="lb-trans"><p>Balchem 在第四季度结束时拥有 7500 万美元现金，并将净债务削减至 8900 万美元，意味着净杠杆约为 0.3 倍。该季度的经营现金流达到 6700 万美元，使得以约 158 美元的平均价格回购约 68.5 万股，并将股息提高 10% 至 0.96 美元。</p>
</div><h2>Science, Clinical Pipeline and Brand Partnerships as Growth Engines</h2>
<div class="lb-trans"><h2>科学、临床管道和品牌合作作为增长引擎</h2>
</div><p>Management underscored more than 20 active clinical studies and 18 publications in 2025 as key assets underpinning future demand and premium positioning. High-profile marketing tie-ups, including sports partnerships for VitaCholine and K2VITAL, are delivering encouraging adoption, while construction has begun on a new microencapsulation facility in New York.</p>
<div class="lb-trans"><p>管理层强调 2025 年有超过 20 项活跃的临床研究和 18 篇出版物作为支撑未来需求和高端定位的关键资产。包括 VitaCholine 和 K2VITAL 的体育合作在内的高调市场营销合作正在带来令人鼓舞的采用，同时在纽约的新微胶囊设施建设已开始。</p>
</div><h2>Sustainability Gains on Emissions, More Work Needed on Water</h2>
<div class="lb-trans"><h2>可持续性在减排方面取得进展，水资源方面仍需努力</h2>
</div><p>On sustainability, Balchem has already exceeded its 2030 greenhouse gas reduction target with a roughly 31% cut versus 2020 levels. Water withdrawal is down about 16% from the same baseline, marking progress but still short of the 25% reduction goal, leaving room for further operational improvements.</p>
<div class="lb-trans"><p>在可持续性方面，Balchem 已经超过了 2030 年温室气体减排目标，与 2020 年水平相比减少了约 31%。水资源提取量较同一基线下降约 16%，虽然取得了进展，但仍未达到 25% 的减排目标，留有进一步改善的空间。</p>
</div><h2>Tariffs, Supply Chain Resilience and FX Tailwinds</h2>
<div class="lb-trans"><h2>关税、供应链韧性和外汇顺风</h2>
</div><p>The company estimated that potential U.S. tariff exposure of about $20 million was cut roughly in half to around $10 million via alternate sourcing and pricing actions. Management also noted that 2025 results benefited modestly from foreign exchange, with USD/EUR moves adding about 0.7% to full-year and just over 1% to Q4 growth.</p>
<div class="lb-trans"><p>公司估计，潜在的美国关税暴露约为 2000 万美元，通过替代采购和定价措施削减至约 1000 万美元。管理层还指出，2025 年的业绩在外汇方面略有受益，美元/欧元的变动为全年增长贡献了约 0.7%，对第四季度增长贡献略超过 1%。</p>
</div><h2>Margins Pressured by Input Costs and Higher Opex</h2>
<div class="lb-trans"><h2>利润率受到投入成本和更高运营费用的压力</h2>
</div><p>Despite higher gross profit dollars in Q4, gross margin slipped about 40 basis points year over year to 35.6% as manufacturing input costs rose. Operating expenses climbed roughly 7% to $42 million, largely due to compensation, partly tempering margin expansion even as underlying earnings remained strong.</p>
<div class="lb-trans"><p>尽管第四季度的毛利润有所增加，但由于制造投入成本上升，毛利率同比下降约 40 个基点至 35.6%。运营费用增长约 7% 至 4200 万美元，主要由于薪酬，部分抑制了利润率的扩张，尽管基础收益依然强劲。</p>
</div><h2>Regulatory and Market Uncertainties Still on the Radar</h2>
<div class="lb-trans"><h2>监管和市场不确定性仍在关注之中</h2>
</div><p>Management flagged a recent high-court decision affecting tariff rules as a source of near-term planning uncertainty, with potential for replacement duties or refunds. They also cited residual tariff cost exposure of about $10 million, early-stage recovery in European monogastric markets, and modest but rising FX sensitivity as areas to monitor.</p>
<div class="lb-trans"><p>管理层指出，最近一项影响关税规则的高等法院裁决是近期规划不确定性的来源，可能会导致替代关税或退款。他们还提到约 1000 万美元的剩余关税成本暴露、欧洲单胃动物市场的早期复苏以及温和但上升的外汇敏感性是需要关注的领域。</p>
</div><h2>Forward-Looking Guidance and Capital Priorities</h2>
<div class="lb-trans"><h2>前瞻性指导和资本优先事项</h2>
</div><p>Looking into 2026, Balchem guided qualitatively to continued top- and bottom-line growth while it advances clinical, capacity, and commercial initiatives. The company asked investors to model an effective tax rate around 23% and reiterated capital priorities of organic investment and acquisitions, debt reduction, sustained dividend growth, and opportunistic buybacks from a low-leverage position.</p>
<div class="lb-trans"><p>展望 2026 年，Balchem 在定性上指导继续实现收入和利润的增长，同时推进临床、产能和商业计划。公司要求投资者将有效税率建模在 23% 左右，并重申有机投资和收购、债务减少、持续的股息增长以及在低杠杆位置下的机会性回购作为资本优先事项。</p>
</div><p>Balchem’s earnings call painted the picture of a company combining steady execution with disciplined balance-sheet management and a science-backed portfolio. Record results, consistent EBITDA growth, and active capital returns are offset by manageable headwinds in input costs and regulation, leaving investors with a generally optimistic outlook on the company’s trajectory.</p>
<div class="lb-trans"><p>拜切公司的财报电话会议描绘了一幅公司稳健执行与严谨资产负债管理相结合的画面。创纪录的业绩、持续的 EBITDA 增长和积极的资本回报被可控的原材料成本和监管压力所抵消，使投资者对公司的发展前景普遍持乐观态度。</p>
</div>

拜切公司收益电话会议突出了创纪录的增长和强劲表现